| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year |
| 12 Nov 2026 | 10-Q |
| 05 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 |
Form 4: Arnold Frances, Director
Sold 11,409 shares ($185K) |
| 29 Oct 2026 | 144 |
| 03 Sep 2026 |
Form 4: Arnold Frances, Director
Sold 1,000 shares ($16K) |
| 02 Sep 2026 | 144 |
| 01 Sep 2026 | 144 |
| 26 Aug 2026 |
8-K: Regulation FD Disclosure
GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients. Dave Singh1, Kapil Mayawala2, Victoria Szenes2, Andreas Eich3, Brian Lea... |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions |
| 15 May 2026 | SCHEDULE 13G |
| 15 May 2026 | SCHEDULE 13G |
| 07 May 2026 | 10-Q |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance |
| 12 Mar 2026 |
Form 3: Pioneering Medicines 02, Llc, 10% owner
Holds 1,562,500 shares of Common Stock |
| 06 Mar 2026 |
Form 4: Nally Michael, Director
Bought 20,000 shares ($240K) |
| 02 Mar 2026 |
Form 4: Vessey Rupert, Director
Granted 29,561 Stock Option (Right to Buy) |
| 02 Mar 2026 |
Form 4: Arnold Frances, Director
Granted 29,561 Stock Option (Right to Buy) |
| 02 Mar 2026 |
Form 4: Martin Sean, Chief Legal Officer & GC
Granted 190,034 Stock Option (Right to Buy) |
Loading...